Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Robert J Motzer,Alain Ravaud,Jean-Jacques Patard,Hardev S Pandha,Daniel J George,Anup Patel,Yen-Hwa Chang,Bernard Escudier,Frede Donskov,Ahmed Magheli,Giacomo Carteni,Brigitte Laguerre,Piotr Tomczak,Jan Breza,Paola Gerletti,Mariajose Lechuga,Xun Lin,Michelle Casey,Lucile Serfass,Allan J Pantuck,Michael Staehler

European Urology（2018）

Cited 182|Views70
No score
Abstract
Further to the positive outcome in the overall S-TRAC population, most subgroups defined by baseline characteristics demonstrated longer disease-free survival on sunitinib versus placebo, including patients with a higher risk of recurrence than the overall population, and patients with Fuhrman grade 3/4.
More
Translated text
Key words
Adjuvant,Disease-free survival,Renal cell carcinoma,Sunitinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined